Timothy O'Brien

List of Publications by Year
in descending order

301 papers	11,854 citations	23879 60 h-index	49824 91 g-index
306 all docs	306 docs citations	306 times ranked	16700 citing authors

#	Article	IF	Citations
1	Professional and personal opinions of doctors in training during the first wave of the COVID19 pandemic. Irish Journal of Medical Science, 2022, 191, 1029-1035.	0.8	4
2	Evaluation of a Community-Based Cardiovascular Prevention Program in Patients With Type 2 Diabetes. American Journal of Health Promotion, 2021, 35, 68-76.	0.9	3
3	Targeting stromal cell Syndecanâ€2 reduces breast tumour growth, metastasis and limits immune evasion. International Journal of Cancer, 2021, 148, 1245-1259.	2.3	12
4	MALDIâ€IMS as a Tool to Determine the Myocardial Response to Syndecanâ€2â€Selected Mesenchymal Stromal Cell Application in an Experimental Model of Diabetic Cardiomyopathy. Proteomics - Clinical Applications, 2021, 15, e2000050.	0.8	8
5	Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data. PLoS ONE, 2021, 16, e0247662.	1.1	8
6	Derivation of iPSC lines from two patients with autism spectrum disorder carrying NRXN1Î± deletion (NUIGi041-A, NUIG041-B; NUIGi045-A) and one sibling control (NUIGi042-A, NUIGi042-B). Stem Cell Research, 2021, 52, 102222.	0.3	0
7	Modelling the relationship between continuously measured glucose and electrocardiographic data in adults with type 1 diabetes mellitus. Endocrinology, Diabetes and Metabolism, 2021, 4, e00263.	1.0	5
8	Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice. Frontiers in Cardiovascular Medicine, 2021, 8, 632728.	1.1	4
9	Derivation of four iPSC lines from a male ASD patient carrying a deletion in the middle coding region of NRXN1Î± gene (NUIGi039-A and NUIGi039-B) and a male sibling control (NUIGi040-A and NUIGi040-B). Stem Cell Research, 2021, 53, 102254.	0.3	0
10	Generation and characterization of three induced pluripotent stem cell lines (NUIGi047-A, NUIGi047-B,) Tj ETQq0 0 0 rgBT /Overlock 10	0.3	0
11	Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe. BMJ Open Diabetes Research and Care, 2021, 9, e002125.	1.2	9
12	Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities. Biomedicines, 2021, 9, 826.	1.4	5
13	Validation of ERICVA Risk Score as a Predictor of One Year Amputation-Free Survival of Patients with Critical Limb Ischemia. Annals of Vascular Surgery, 2021, 75, 171-178.	0.4	1
14	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	1.0	23
15	NRXN1Î±+/- is associated with increased excitability in ASD iPSC-derived neurons. BMC Neuroscience, 2021, 22, 56.	0.8	14
16	When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease. Frontiers in Medicine, 2021, 8, 728496.	1.2	14
17	Derivation and characterization of two human induced pluripotent stem cell lines (NUIGi004-A) and (NUIGi012-A) from two patients with LQT2 disease. Stem Cell Research, 2021, 56, 102555.	0.3	1
18	Generation and characterization of three induced pluripotent stem cell lines (NUIGi046-A, NUIGi046-B,) Tj ETQq0 0 0 rgBT /Overlock 10	0.3	0

#	Article	IF	Citations
19	Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A). Stem Cell Research, 2020, 43, 101665.	0.3	3
20	Generation and characterization of an induced pluripotent stem cell (iPSC) line (NUIGi003-A) from a long QT syndrome type 2 (LQT2) patient harbouring the KCNH2 c.2464G>A pathogenic variant. Stem Cell Research, 2020, 49, 101997.	0.3	2
21	Generation and characterization of two induced pluripotent stem cell lines (NUIGi038-A, NUIGi038-B) from dermal fibroblasts of a healthy individual. Stem Cell Research, 2020, 49, 101996.	0.3	3
22	Autologous bone marrow mesenchymal stromal cell therapy for â€œno-optionâ€•critical limb ischemia is limited by karyotype abnormalities. Cytotherapy, 2020, 22, 313-321.	0.3	26
23	Temporal changes guided by mesenchymal stem cells on a 3D microgel platform enhance angiogenesis in vivo at a low-cell dose. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19033-19044.	3.3	45
24	The Functionality of Endothelial-Colony-Forming Cells from Patients with Diabetes Mellitus. Cells, 2020, 9, 1731.	1.8	10
25	Derivation of iPSC lines from three young healthy donors of Caucasian origin (NUIGi035-A; NUIGi036-A;) Tj ETQq1 1 0.784314 rgBT /O	0.3	0
26	Induced pluripotent stem cell line derived from a sporadic amyotrophic lateral sclerosis patient. Stem Cell Research, 2020, 45, 101841.	0.3	0
27	Generation of three induced pluripotent stem cell (iPSC) lines from a patient with developmental epileptic encephalopathy due to the pathogenic KCNA2 variant c.869T>G; p.Leu290Arg (NUIGi052-A,) Tj ETQq1 0.784314 rgBT /O	0.3	4
28	Administration of Human Non-Diabetic Mesenchymal Stromal Cells to a Murine Model of Diabetic Fracture Repair: A Pilot Study. Cells, 2020, 9, 1394.	1.8	4
29	Umbilical cord-derived CD362+ mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy. Stem Cell Research and Therapy, 2020, 11, 116.	2.4	24
30	Generation of twelve induced pluripotent stem cell lines from two healthy controls and two patients with sporadic amyotrophic lateral sclerosis. Stem Cell Research, 2020, 44, 101752.	0.3	2
31	Derivation of two iPSC lines from a sporadic ASD patient (NUIGi033-A) and a paternal control (NUIGi034-A). Stem Cell Research, 2020, 44, 101722.	0.3	1
32	Knowledge, Perceptions and Concerns of Diabetes-Associated Complications among Individuals Living with Type 1 and Type 2 Diabetes Mellitus. Healthcare (Switzerland), 2020, 8, 25.	1.0	13
33	Impact of Type 2 Diabetes Mellitus on Human Bone Marrow Stromal Cell Number and Phenotypic Characteristics. International Journal of Molecular Sciences, 2020, 21, 2476.	1.8	27
34	Biallelic CYP24A1 variants presenting during pregnancy: clinical and biochemical phenotypes. Endocrine Connections, 2020, 9, 530-541.	0.8	14
35	Is flat dosing cost-effective? Re: â€˜The same old storyâ€™: thoughts on authorised doses of anticancer drugs. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097420.	1.4	0
36	Generation of eight human induced pluripotent stem cell (iPSC) lines from familial Long QT Syndrome type 1 (LQT1) patients carrying KCNQ1 c.1697C>A mutation (NUIGi005-A, NUIGi005-B, NUIGi005-C,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	4

#	Article	IF	Citations
37	Long QT Syndrome: Genetics and Future Perspective. Pediatric Cardiology, 2019, 40, 1419-1430.	0.6	83
38	Generation of six induced pluripotent stem cell (iPSC) lines from two patients with amyotrophic lateral sclerosis (NUIGi043-A, NUIGi043-B, NUIGi043-C, NUIGi044-A, NUIGi044-B, NUIGi044-C). Stem Cell Research, 2019, 40, 101558.	0.3	4
39	Generation and characterization of a human induced pluripotent stem cell (iPSC) line (HEBHMUi001-A) from a sporadic Parkinson's disease patient. Stem Cell Research, 2019, 36, 101417.	0.3	11
40	Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Non-coding RNA, 2019, 5, 31.	1.3	14
41	Derivation of familial iPSC lines from three ASD patients carrying NRXN1Î± and two controls (NUIGi022-A, NUIGi022-B; NUIGi023-A, NUIGi023-B; NUIGi025-A, NUIGi025-B; NUIGi024-A, NUIGi024-B;) Tj ETQq1 1 0.784314 rgBT /Ov	0.3	4
42	Generation and characterization of twelve human induced pluripotent stem cell (iPSC) lines from four familial long QT syndrome type 1 (LQT1) patients carrying KCNQ1 c.1201dupC mutation. Stem Cell Research, 2019, 41, 101650.	0.3	7
43	Increased Ca2+ signaling in NRXN1Î±+/â^' neurons derived from ASD induced pluripotent stem cells. Molecular Autism, 2019, 10, 52.	2.6	33
44	Phenotypic and functional heterogeneity of human intermediate monocytes based on <scp>HLA</scp>â€<scp>DR</scp> expression. Immunology and Cell Biology, 2018, 96, 742-758.	1.0	14
45	A 3-month Safety Assessment of Human Bone Marrow Derived Mesenchymal Stromal Cells Administered Once by the Intramuscular Route to Immunodeficient Mice. Toxicologic Pathology, 2018, 46, 290-301.	0.9	3
46	The Vasoreparative Function of Myeloid Angiogenic Cells Is Impaired in Diabetes Through the Induction of IL1Î². Stem Cells, 2018, 36, 834-843.	1.4	17
47	Antiâ€donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells. Immunology and Cell Biology, 2018, 96, 536-548.	1.0	5
48	Ulk4 regulates GABAergic signaling and anxiety-related behavior. Translational Psychiatry, 2018, 8, 43.	2.4	20
49	Tissue Engineering: Toward Customized Extracellular Niche Engineering: Progress in Cellâ€Entrapment Technologies (Adv. Mater. 1/2018). Advanced Materials, 2018, 30, 1870006.	11.1	1
50	Ulk4 deficiency leads to hypomyelination in mice. Glia, 2018, 66, 175-190.	2.5	26
51	Toward Customized Extracellular Niche Engineering: Progress in Cellâ€Entrapment Technologies. Advanced Materials, 2018, 30, 1703948.	11.1	51
52	Syndecan-2â€“positive, Bone Marrowâ€“derived Human Mesenchymal Stromal Cells Attenuate Bacterial-induced Acute Lung Injury and Enhance Resolution of Ventilator-induced Lung Injury in Rats. Anesthesiology, 2018, 129, 502-516.	1.3	45
53	Recent Advances in Endothelial Progenitor Cells Toward Their Use in Clinical Translation. Frontiers in Medicine, 2018, 5, 354.	1.2	55
54	The chemistry and topography of stabilized and functionalized graphene oxide coatings. Plasma Processes and Polymers, 2018, 15, 1800084.	1.6	11

#	Article	IF	Citations
55	Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reactionâ€“based detection of human DNA in murine organs. Cytotherapy, 2017, 19, 384-394.	0.3	29
56	Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers. Scientific Reports, 2017, 7, 46731.	1.6	64
57	Multiple roles of Ulk4 in neurogenesis and brain function. Neurogenesis (Austin, Tex), 2017, 4, e1313646.	1.5	15
58	Influence of Referral to a Combined Diabetology and Nephrology Clinic on Renal Functional Trends and Metabolic Parameters in Adults With Diabetic Kidney Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 150-160.	1.2	10
59	Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Molecular Brain, 2017, 10, 22.	1.3	101
60	Ulk4 Regulates Neural Stem Cell Pool. Stem Cells, 2016, 34, 2318-2331.	1.4	26
61	Scaffold and scaffoldâ€free selfâ€assembled systems in regenerative medicine. Biotechnology and Bioengineering, 2016, 113, 1155-1163.	1.7	34
62	Variability in Endogenous Perfusion Recovery of Immunocompromised Mouse Models of Limb Ischemia. Tissue Engineering - Part C: Methods, 2016, 22, 370-381.	1.1	19
63	Co-transfection of decorin and interleukin-10 modulates pro-fibrotic extracellular matrix gene expression in human tenocyte culture. Scientific Reports, 2016, 6, 20922.	1.6	30
64	The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease. Current Diabetes Reports, 2016, 16, 42.	1.7	45
65	Immunomodulatory effects of natural polysaccharides assessed in human whole blood culture and THP-1 cells show greater sensitivity of whole blood culture. International Immunopharmacology, 2016, 36, 315-323.	1.7	9
66	Ulk4 Is Essential for Ciliogenesis and CSF Flow. Journal of Neuroscience, 2016, 36, 7589-7600.	1.7	36
67	Rapamycin regulates autophagy and cell adhesion in induced pluripotent stem cells. Stem Cell Research and Therapy, 2016, 7, 166.	2.4	74
68	Macromolecular crowding meets oxygen tension in human mesenchymal stem cell culture - A step closer to physiologically relevant in vitro organogenesis. Scientific Reports, 2016, 6, 30746.	1.6	66
69	In vitro models for assessing therapeutic angiogenesis. Drug Discovery Today, 2016, 21, 1495-1503.	3.2	25
70	Differentiation of Vascular Stem Cells Contributes to Ectopic Calcification of Atherosclerotic Plaque. Stem Cells, 2016, 34, 913-923.	1.4	38
71	Endothelial nitric oxide synthase induces heat shock protein HSPA6 (HSP70Bâ€²) in human arterial smooth muscle cells. Nitric Oxide - Biology and Chemistry, 2016, 52, 41-48.	1.2	16
72	Therapeutic Efficacy of Human Mesenchymal Stromal Cells in the Repair of Established Ventilator-induced Lung Injury in the Rat. Anesthesiology, 2015, 122, 363-373.	1.3	57

#	Article	IF	Citations
73	ROCK activity and the GÎ²Î³ complex mediate chemotactic migration of mouse bone marrow-derived stromal cells. Stem Cell Research and Therapy, 2015, 6, 136.	2.4	10
74	Expression of Concern: Human amniotic epithelial cells can differentiate into granulosa cells and restore folliculogenesis in a mouse model of chemotherapy-induced premature ovarian failure. Stem Cell Research and Therapy, 2015, 6, 240.	2.4	2
75	Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. Stem Cells, 2015, 33, 2726-2737.	1.4	97
76	Inefficiency in macromolecular transport of <scp>SCS</scp>â€based microcapsules affects viability of primary human mesenchymal stem cells but not of immortalized cells. Journal of Biomedical Materials Research - Part A, 2015, 103, 3676-3688.	2.1	3
77	Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax, 2015, 70, 625-635.	2.7	163
78	An injectable elastin-based gene delivery platform for dose-dependent modulation of angiogenesis and inflammation for critical limb ischemia. Biomaterials, 2015, 65, 126-139.	5.7	53
79	Translating stem cell research to the clinic: a primer on translational considerations for your first stem cell protocol. Stem Cell Research and Therapy, 2015, 6, 146.	2.4	14
80	Aerosol-Mediated Delivery of AAV2/6-IÎºBÎ± Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rats. Human Gene Therapy, 2015, 26, 36-46.	1.4	6
81	Isolation of Endothelial Progenitor Cells (EPCs). , 2015, , 45-54.		1
82	MSCs Isolated From Patients With Ischemic Vascular Disease Have Normal Angiogenic Potential. Molecular Therapy, 2014, 22, 1888-1889.	3.7	5
83	Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus. Frontiers in Endocrinology, 2014, 5, 86.	1.5	72
84	The Potential of Cell-based Therapy for Diabetes and Diabetes-related Vascular Complications. Current Diabetes Reports, 2014, 14, 469.	1.7	13
85	Assessment of stem cell carriers for tendon tissue engineering in pre-clinical models. Stem Cell Research and Therapy, 2014, 5, 38.	2.4	61
86	A shape-controlled tuneable microgel platform to modulate angiogenic paracrine responses in stem cells. Biomaterials, 2014, 35, 8757-8766.	5.7	79
87	Comparison of Cellular Architecture, Axonal Growth, and Blood Vessel Formation Through Cell-Loaded Polymer Scaffolds in the Transected Rat Spinal Cord. Tissue Engineering - Part A, 2014, 20, 2985-2997.	1.6	38
88	Use of a fibrin-based system for enhancing angiogenesis and modulating inflammation in the treatment of hyperglycemic wounds. Biomaterials, 2014, 35, 2001-2010.	5.7	45
89	Three years of Stem Cell Research & Therapy. Stem Cell Research and Therapy, 2013, 4, 46.	2.4	0
90	Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia. Critical Care, 2013, 17, R82.	2.5	24

#	Article	IF	Citations
91	Robust, Efficient, and Practical Electrogene Transfer Method for Human Mesenchymal Stem Cells Using Square Electric Pulses. Human Gene Therapy Methods, 2013, 24, 289-297.	2.1	31
92	Autologous circulating angiogenic cells treated with osteopontin and delivered via a collagen scaffold enhance wound healing in the alloxan-induced diabetic rabbit ear ulcer model. Stem Cell Research and Therapy, 2013, 4, 158.	2.4	24
93	Liposomal surface coatings of metal stents for efficient non-viral gene delivery to the injured vasculature. Journal of Controlled Release, 2013, 167, 109-119.	4.8	14
94	Mesenchymal Stem Cell Survival in the Infarcted Heart Is Enhanced by Lentivirus Vector-Mediated Heat Shock Protein 27 Expression. Human Gene Therapy, 2013, 24, 840-851.	1.4	90
95	Impact of Mesenchymal Stem Cell secreted PAI-1 on colon cancer cell migration and proliferation. Biochemical and Biophysical Research Communications, 2013, 435, 574-579.	1.0	42
96	The behavioural and neuropathological impact of intranigral AAV-Î±-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behavioural Brain Research, 2013, 243, 6-15.	1.2	26
97	High levels of ephrinB2 over-expression increases the osteogenic differentiation of human mesenchymal stem cells and promotes enhanced cell mediated mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix. Journal of Controlled Release, 2013, 165, 173-182.	4.8	52
98	Gene Therapy for Type 1 Diabetes Moves a Step Closer to Reality. Diabetes, 2013, 62, 1396-1397.	0.3	1
99	Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials, 2013, 34, 1987-1994.	5.7	124
100	Restructuring of the Diabetes Day Centre: a pilot lean project in a tertiary referral centre in the West of Ireland. BMJ Quality and Safety, 2013, 22, 681-688.	1.8	19
101	Topical Administration of Allogeneic Mesenchymal Stromal Cells Seeded in a Collagen Scaffold Augments Wound Healing and Increases Angiogenesis in the Diabetic Rabbit Ulcer. Diabetes, 2013, 62, 2588-2594.	0.3	115
102	Effects of Intratracheal Mesenchymal Stromal Cell Therapy during Recovery and Resolution after Ventilator-induced Lung Injury. Anesthesiology, 2013, 118, 924-932.	1.3	92
103	Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax, 2012, 67, 496-501.	2.7	238
104	Pretreatment of Endothelial Progenitor Cells with Osteopontin Enhances Cell Therapy for Peripheral Vascular Disease. Cell Transplantation, 2012, 21, 1095-1107.	1.2	31
105	Interference: an alteRNAtive therapy following acute myocardial infarction. Trends in Pharmacological Sciences, 2012, 33, 635-645.	4.0	8
106	A Role for MRP8 in in stent restenosis in diabetes. Atherosclerosis, 2012, 221, 325-332.	0.4	13
107	Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Research and Therapy, 2012, 3, 28.	2.4	143
108	Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-Î±-synuclein and the pesticide, rotenone. Neuroscience, 2012, 203, 170-179.	1.1	36

#	Article	IF	Citations
109	Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries. Trials, 2012, 13, 27.	0.7	9
110	Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine, 2012, 16, 2094-2103.	1.6	215
111	Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model. Gene Therapy, 2012, 19, 321-328.	2.3	43
112	Lentiviral vector delivery of short hairpin RNA to NG2 and neurotrophin-3 promotes locomotor recovery in injured rat spinal cord. Cytotherapy, 2012, 14, 1235-1244.	0.3	22
113	A comparison of the efficacy of transplantation of bone marrow-derived mesenchymal stem cells and unrestricted somatic stem cells on outcome after acute myocardial infarction. Stem Cell Research and Therapy, 2012, 3, 36.	2.4	20
114	Stem Cell Research & Therapy in 2012. Stem Cell Research and Therapy, 2012, 3, 16.	2.4	1
115	Mesenchymal Stem Cells: Clinical Applications (An Overview). , 2012, , 161-175.		0
116	Recovery of cardiac function mediated by MSC and interleukin-10 plasmid functionalised scaffold. Biomaterials, 2012, 33, 1303-1314.	5.7	63
117	Adenoviral Transduction of Mesenchymal Stem Cells: In Vitro Responses and In Vivo Immune Responses after Cell Transplantation. PLoS ONE, 2012, 7, e42662.	1.1	31
118	Stem Cell Research & Therapy marks its first anniversary. Stem Cell Research and Therapy, 2011, 2, 22.	2.4	2
119	A Temporal Gene Delivery System Based on Fibrin Microspheres. Molecular Pharmaceutics, 2011, 8, 439-446.	2.3	28
120	Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia. Stem Cell Research and Therapy, 2011, 2, 12.	2.4	89
121	Stem cell therapy for cardiac disease. Expert Opinion on Biological Therapy, 2011, 11, 177-187.	1.4	28
122	Functionalized Scaffold-mediated Interleukin 10 Gene Delivery Significantly Improves Survival Rates of Stem Cells In Vivo. Molecular Therapy, 2011, 19, 969-978.	3.7	38
123	Overexpression of pulmonary extracellular superoxide dismutase attenuates endotoxin-induced acute lung injury. Intensive Care Medicine, 2011, 37, 1680-7.	3.9	20
124	Mesenchymal Stem Cell-Mediated Delivery of the Sodium Iodide Symporter Supports Radionuclide Imaging and Treatment of Breast Cancer. Stem Cells, 2011, 29, 1149-1157.	1.4	76
125	Thermosensitive hydrogel for prolonged delivery of lentiviral vector expressing neurotrophinâ€3 in vitro. Journal of Gene Medicine, 2011, 13, 591-601.	1.4	20
126	Differential miRNA Expression in Omental Adipose Tissue and in the Circulation of Obese Patients Identifies Novel Metabolic Biomarkers. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E846-E850.	1.8	190

#	Article	IF	Citations
127	Developing Cell-Specific Antibodies to Endothelial Progenitor Cells Using Avian Immune Phage Display Technology. Journal of Biomolecular Screening, 2011, 16, 744-754.	2.6	10
128	Î² Cell Protection by Inhibition of iNOS Through Lentiviral Vector-Based Strategies. Methods in Molecular Biology, 2011, 704, 153-168.	0.4	9
129	Relevance of an Academic GMP Pan-European Vector Infra-Structure (PEVI). Current Gene Therapy, 2010, 10, 414-422.	0.9	4
130	Mesenchymal Stem Cells Overexpressing Ephrin-B2 Rapidly Adopt an Early Endothelial Phenotype with Simultaneous Reduction of Osteogenic Potential. Tissue Engineering - Part A, 2010, 16, 2755-2768.	1.6	36
131	Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Research and Treatment, 2010, 124, 317-326.	1.1	270
132	Liposomal gene delivery mediated by tissue-engineered scaffolds. Trends in Biotechnology, 2010, 28, 28-36.	4.9	72
133	General practitioners' attitudes and preparedness towards Clinical Decision Support in e-Prescribing (CDS-eP) adoption in the West of Ireland: a cross sectional study. BMC Medical Informatics and Decision Making, 2010, 10, 2.	1.5	25
134	Enhanced lipoplexâ€mediated gene expression in mesenchymal stem cells using reiterated nuclear localization sequence peptides. Journal of Gene Medicine, 2010, 12, 207-218.	1.4	38
135	Lentiviral vectorâ€mediated knockdown of the neuroglycan 2 proteoglycan or expression of neurotrophinâ€3 promotes neurite outgrowth in a cell culture model of the glial scar. Journal of Gene Medicine, 2010, 12, 863-872.	1.4	22
136	Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials, 2010, 11, 104.	0.7	42
137	Nonâ€viral gene therapy for myocardial engineering. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2010, 2, 232-248.	3.3	16
138	Introduction to Series on Mesenchymal Stromal (Stem) Cellsâ€"MSCs. Human Gene Therapy, 2010, 21, 1037-1038.	1.4	0
139	Bolus Delivery of Mesenchymal Stem Cells to Injured Vasculature in the Rabbit Carotid Artery Produces a Dysfunctional Endothelium. Tissue Engineering - Part A, 2010, 16, 1657-1665.	1.6	5
140	Translation of science to surgery. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 1195-1202.	3.4	13
141	Engraftment, migration and differentiation of neural stem cells in the rat spinal cord following contusion injury. Cytotherapy, 2010, 12, 313-325.	0.3	16
142	Review Paper: Basic Concepts to Novel Therapies: A Review of the Diabetic Foot. International Journal of Lower Extremity Wounds, 2010, 9, 90-102.	0.6	75
143	Journeys to High Altitudeâ€"Risks and Recommendations for Travelers with Preexisting Medical Conditions. Journal of Travel Medicine, 2010, 17, 48-62.	1.4	81
144	HPLC Purification of Adenoviral Vectors. Methods in Molecular Biology, 2010, 594, 395-408.	0.4	3

#	Article	IF	Citations
145	Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Research and Therapy, 2010, 1, 25.	2.4	97
146	Welcome to Stem Cell Research & Therapy. Stem Cell Research and Therapy, 2010, 1, .	2.4	39
147	Generation of Antioxidant Adenovirus Gene Transfer Vectors Encoding CuZnSOD, MnSOD, and Catalase. Methods in Molecular Biology, 2010, 594, 381-393.	0.4	6
148	Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease. Discovery Medicine, 2010, 9, 219-23.	0.5	17
149	Nitric oxide synthase gene therapy: progress and prospects. Expert Opinion on Biological Therapy, 2009, 9, 867-878.	1.4	38
150	Neurotrophic Factorâ€“Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord Without Differentiating into Neural Cells. Tissue Engineering - Part A, 2009, 15, 3049-3059.	1.6	43
151	Hypercapnic acidosis attenuates pulmonary epithelial wound repair by an NF-ÂB dependent mechanism. Thorax, 2009, 64, 976-982.	2.7	104
152	Current tissue engineering and novel therapeutic approaches to axonal regeneration following spinal cord injury using polymer scaffolds. Respiratory Physiology and Neurobiology, 2009, 169, 183-199.	0.7	161
153	A matrix reservoir for improved control of non-viral gene delivery. Journal of Controlled Release, 2009, 136, 220-225.	4.8	66
154	Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. International Journal of Cancer, 2009, 124, 326-332.	2.3	116
155	Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. Journal of Biomedical Materials Research - Part A, 2009, 89A, 876-884.	2.1	36
156	Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography. Journal of Gene Medicine, 2009, 11, 978-989.	1.4	39
157	Common definition for categories of clinical research: a prerequisite for a survey on regulatory requirements by the European Clinical Research Infrastructures Network (ECRIN). Trials, 2009, 10, 95.	0.7	15
158	Effect of cyclosporin A on functional recovery in the spinal cord following contusion injury. Journal of Anatomy, 2009, 215, 267-279.	0.9	19
159	Fibrinâ^Lipoplex System for Controlled Topical Delivery of Multiple Genes. Biomacromolecules, 2009, 10, 1650-1654.	2.6	31
160	Elevation of cAMP in Mesenchymal Stem Cells Transiently Upregulates Neural Markers Rather than Inducing Neural Differentiation. Stem Cells and Development, 2009, 18, 387-398.	1.1	46
161	Bone Marrowâ€“Derived Mesenchymal Stem Cells Promote Angiogenic Processes in a Time- and Dose-Dependent MannerIn Vitro. Tissue Engineering - Part A, 2009, 15, 2459-2470.	1.6	127
162	Fibrin as a Delivery System for Therapeutic Drugs and Biomolecules. Tissue Engineering - Part B: Reviews, 2009, 15, 201-214.	2.5	128

#	Article	IF	Citations
163	Optimized Aerosol Delivery to a Mechanically Ventilated Rodent. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2009, 22, 323-332.	0.7	35
164	Comparison of Viral and Nonviral Vectors for Gene Transfer to Human Endothelial Progenitor Cells. Tissue Engineering - Part C: Methods, 2009, 15, 223-231.	1.1	25
165	Stem Cell Therapy and Regenerative Medicine. Mayo Clinic Proceedings, 2009, 84, 859-861.	1.4	28
166	Stem cell therapy and regenerative medicine. Mayo Clinic Proceedings, 2009, 84, 859-61.	1.4	13
167	Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. Journal of General Virology, 2009, 90, 2622-2633.	1.3	34
168	When a nephrectomy cures hypoglycaemia. BMJ Case Reports, 2009, 2009, bcr0220091617-bcr0220091617.	0.2	3
169	Gene delivery to the vasculature mediated by lowâ€titre adenoâ€associated virus serotypes 1 and 5. Journal of Gene Medicine, 2008, 10, 143-151.	1.4	22
170	The use of therapeutic gene eNOS delivered via a fibrin scaffold enhances wound healing in a compromised wound model. Biomaterials, 2008, 29, 3143-3151.	5.7	62
171	Metabolic Flexibility Permits Mesenchymal Stem Cell Survival in an Ischemic Environment. Stem Cells, 2008, 26, 1325-1336.	1.4	165
172	Endothelial progenitor cells for the treatment of diabetic vasculopathy: panacea or Pandoraâ€™s box?. Diabetes, Obesity and Metabolism, 2008, 10, 353-366.	2.2	15
173	Cytokineâ€induced Î²â€cell apoptosis is NOâ€dependent, mitochondriaâ€mediated and inhibited by BCLâ€X_L. Journal of Cellular and Molecular Medicine, 2008, 12, 591-606.	1.6	56
174	Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. Journal of Cellular and Molecular Medicine, 2008, 12, 2628-2643.	1.6	99
175	Assessment of Wound Healing in the Alloxan-Induced Diabetic Rabbit Ear Model. Journal of Investigative Surgery, 2008, 21, 261-269.	0.6	26
176	Genetic engineering of the blood vessel wall to improve nitric oxide bioavailability. Bio-Medical Materials and Engineering, 2008, 18, 301-302.	0.4	0
177	Gene-Modified Mesenchymal Stem Cells Express Functionally Active Nerve Growth Factor on an Engineered Poly Lactic Glycolic Acid (PLGA) Substrate. Tissue Engineering - Part A, 2008, 14, 681-690.	1.6	48
178	Gene-eluting Stents: Adenovirus-mediated Delivery of eNOS to the Blood Vessel Wall Accelerates Re-endothelialization and Inhibits Restenosis. Molecular Therapy, 2008, 16, 1674-1680.	3.7	78
179	Tripartite Meeting in Gene and Cell Therapy, 2008: Irish Society for Gene and Cell Therapy, British Society for Gene Therapy, and International Society for Cell and Gene Therapy of Cancer. Human Gene Therapy, 2008, 19, 967-978.	1.4	2
180	Comparative evaluation of viral, nonviral and physical methods of gene delivery to normal and transformed lung epithelial cells. Anti-Cancer Drugs, 2008, 19, 783-788.	0.7	12

#	Article	IF	Citations
181	Genetic engineering of the blood vessel wall to improve nitric oxide bioavailability. Bio-Medical Materials and Engineering, 2008, 18, 301-2.	0.4	0
182	Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells. Clinical Cancer Research, 2007, 13, 5020-5027.	3.2	399
183	OxLDL-induced gene expression patterns in CASMC are mimicked in apoEâ^'/â^' mice aortas. Biochemical and Biophysical Research Communications, 2007, 356, 681-686.	1.0	6
184	Î² Cell cytoprotection using lentiviral vector-based iNOS-specific shRNA delivery. Biochemical and Biophysical Research Communications, 2007, 357, 75-80.	1.0	12
185	Recombinant Adenoviral Gene Transfer Does Not Affect Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2007, 26, 1281-1285.	0.3	3
186	UC blood-derived mesenchymal stromal cells: an overview. Cytotherapy, 2007, 9, 717-726.	0.3	102
187	Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury. Gene Therapy, 2007, 14, 396-404.	2.3	68
188	Cardiovascular gene therapy: current status and therapeutic potential. British Journal of Pharmacology, 2007, 152, 175-188.	2.7	80
189	Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bclâ€xL. Journal of Cellular and Molecular Medicine, 2007, 11, 509-520.	1.6	78
190	The Rational Design of Î² Cell Cytoprotective Gene Transfer Strategies: Targeting Deleterious iNOS Expression. Molecular Biotechnology, 2007, 37, 38-47.	1.3	9
191	Gene Transfer into Rat Mesenchymal Stem Cells: A Comparative Study of Viral and Nonviral Vectors. Stem Cells and Development, 2006, 15, 87-96.	1.1	142
192	Gene-Eluting Stents: Comparison of Adenoviral and Adeno- Associated Viral Gene Delivery to the Blood Vessel Wall In Vivo. Human Gene Therapy, 2006, 17, 741-750.	1.4	48
193	Î² cell cytoprotective strategies: Establishing the relative roles for iNOS and ROS. Biochemical and Biophysical Research Communications, 2006, 342, 1240-1248.	1.0	30
194	ER stress contributes to ischemia-induced cardiomyocyte apoptosis. Biochemical and Biophysical Research Communications, 2006, 349, 1406-1411.	1.0	185
195	Vitamin D insufficiency in older female community-dwelling acute hospital admissions and the response to supplementation. European Journal of Clinical Nutrition, 2006, 60, 1009-1015.	1.3	27
196	Endothelial progenitor cells: diagnostic and therapeutic considerations. BioEssays, 2006, 28, 261-270.	1.2	84
197	Cytoprotection of beta cells: rational gene transfer strategies. Diabetes/Metabolism Research and Reviews, 2006, 22, 241-252.	1.7	16
198	Optimization of a fibrin scaffold for sustained release of an adenoviral gene vector. Journal of Biomedical Materials Research - Part A, 2006, 78A, 702-708.	2.1	37

#	Article	IF	Citations
199	Distinct Effects of High-Glucose Conditions on Endothelial Cells of Macrovascular and Microvascular Origins. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 9-16.	1.7	30
200	Adenoviral-Mediated Gene Transfer of Nitric Oxide Synthase Isoforms and Vascular Cell Proliferation. Journal of Vascular Research, 2006, 43, 462-472.	0.6	28
201	Analysis of Superoxide Anion Production in Tissue. , 2005, 108, 065-072.		21
202	Gene Transfer in Endothelial Dysfunction and Hypertension. , 2005, 108, 299-314.		5
203	Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. Journal of Cellular and Molecular Medicine, 2005, 9, 609-622.	1.6	97
204	Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques. Gene Therapy, 2005, 12, S62-S72.	2.3	34
205	In vivo expression and function of recombinant GTPCH I in the rabbit carotid artery. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H570-H574.	1.5	6
206	Current status of catheter- and stent-based gene therapy. Cardiovascular Research, 2004, 64, 208-216.	1.8	60
207	When head rules heart. Lancet, The, 2004, 364, 1828.	6.3	0
208	Mastopathy and diabetes. Current Diabetes Reports, 2003, 3, 56-59.	1.7	20
209	Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 998-1006.	0.4	23
210	A direct mechanical method for accurate and efficient adenoviral vector delivery to tissues. Gene Therapy, 2003, 10, 443-452.	2.3	16
211	In Vivo Gene Transfer of Inducible Nitric Oxide Synthase to Carotid Arteries From Hypercholesterolemic Rabbits. Stroke, 2003, 34, 1293-1298.	1.0	20
212	"Diabetic Mastopathy," or Sclerosing Lymphocytic Lobulitis, Is Strongly Associated With Type 1 Diabetes. Diabetes Care, 2002, 25, 121-126.	4.3	71
213	Protective Vasomotor Effects of In Vivo Recombinant Endothelial Nitric Oxide Synthase Gene Expression in a Canine Model of Cerebral Vasospasm. Stroke, 2002, 33, 782-789.	1.0	59
214	Dietary antioxidants preserve endothelium dependent vasorelaxation in overfed rats. Atherosclerosis, 2002, 161, 327-333.	0.4	23
215	Gene transfer to coronary artery bypass conduits. Annals of Thoracic Surgery, 2002, 74, 1161-1166.	0.7	14
216	Adenoviral-mediated overexpression of catalase inhibits endothelial cell proliferation. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H2620-H2626.	1.5	35

#	Article	IF	Citations
217	Inhibitory effect of recombinant iNOS gene expression on vasomotor function of canine basilar artery. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H2560-H2566.	1.5	21
218	Expression and Function of Recombinant S1179D Endothelial Nitric Oxide Synthase in Canine Cerebral Arteries. Stroke, 2002, 33, 1071-1076.	1.0	19
219	Effects of Immunosuppressants on Receptor Activator of NF-Î¹B Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 2001, 280, 334-339.	1.0	196
220	Remnant Lipoproteins Induce Endothelial Plasminogen Activator Inhibitor-1. Biochemical and Biophysical Research Communications, 2001, 285, 15-19.	1.0	11
221	Low-Density Lipoprotein Apheresis for the Treatment of Refractory Hyperlipidemia. Mayo Clinic Proceedings, 2001, 76, 1039-1046.	1.4	27
222	Gene transfer of superoxide dismutase isoforms reverses endothelial dysfunction in diabetic rabbit aorta. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H2516-H2523.	1.5	55
223	Gene Transfer of Manganese Superoxide Dismutase Reverses Vascular Dysfunction in the Absence But Not in the Presence of Atherosclerotic Plaque. Human Gene Therapy, 2001, 12, 1407-1416.	1.4	36
224	Superoxide Anions and Endothelial Cell Proliferation in Normoglycemia and Hyperglycemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 195-200.	1.1	46
225	Efficacy of adenoviral gene transfer with manganese superoxide dismutase and endothelial nitric oxide synthase in reducing ischemia and reperfusion injury. European Journal of Cardio-thoracic Surgery, 2001, 20, 153-158.	0.6	48
226	Conditions of vector delivery improve efficiency of adenoviral-mediated gene transfer to the transplanted heart. European Journal of Cardio-thoracic Surgery, 2001, 19, 702-707.	0.6	9
227	THE EFFECTS OF CTLA-4Ig ON ACUTE LUNG ALLOGRAFT REJECTION: A COMPARISON OF INTRABRONCHIAL GENE THERAPY WITH SYSTEMIC ADMINISTRATION OF PROTEIN1. Transplantation, 2001, 71, 1867-1871.	0.5	10
228	In Vivo Gene Transfer of Endothelial Nitric Oxide Synthase to Carotid Arteries From Hypercholesterolemic Rabbits Enhances Endothelium-Dependent Relaxations. Stroke, 2000, 31, 968-975.	1.0	33
229	Adenovirus-Mediated Gene Transfer to Human Cerebral Arteries. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 1360-1371.	2.4	31
230	Improved efficiency of gene transfer to the transplanted lung by retrograde vascular gene delivery. Transplant International, 2000, 13, 241-246.	0.8	4
231	Gene transfer of endothelial nitric oxide synthase to pulmonary allografts: impact on acute rejection. Transplant International, 2000, 13, S591-S596.	0.8	6
232	Highly efficient ex vivo gene transfer to the transplanted heart by means of hypothermic perfusion with a low dose of adenoviral vector. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 493-500.	0.4	18
233	Gene transfer of endothelial nitric oxide synthase alters endothelium-dependent relaxations in aortas from diabetic rabbits. Diabetologia, 2000, 43, 340-347.	2.9	35
234	Gene transfer of endothelial nitric oxide synthase to pulmonary allografts: impact on acute rejection. Transplant International, 2000, 13, S591-S596.	0.8	3

#	Article	IF	Citations
235	B1 and B2 bradykinin receptors on adventitial fibroblasts of cerebral arteries are coupled to recombinant eNOS. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H367-H372.	1.5	14
236	Effects of recombinant eNOS gene expression on reactivity of small cerebral arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H420-H427.	1.5	20
237	Expression and Function of Recombinant Endothelial Nitric Oxide Synthase in Human Endothelial Cells. Journal of Vascular Research, 2000, 37, 449-456.	0.6	16
238	Adenoviral Vectors and Gene Transfer to the Blood Vessel Wall. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1414-1416.	1.1	12
239	Inhibition of Adrenal Cell Aldosterone Synthesis by Endogenous Nitric Oxide Release. Hypertension, 2000, 35, 324-328.	1.3	35
240	eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovascular Research, 2000, 47, 697-706.	1.8	70
241	Gene Therapy for Atherosclerotic Cardiovascular Disease: In Response. Mayo Clinic Proceedings, 2000, 75, 1223.	1.4	0
242	Gene Therapy for Atherosclerotic Cardiovascular Disease: A Time for Optimism and Caution. Mayo Clinic Proceedings, 2000, 75, 831-834.	1.4	17
243	Prospective Evaluation of Roux-en-Y Gastric Bypass as Primary Operation for Medically Complicated Obesity. Mayo Clinic Proceedings, 2000, 75, 673-680.	1.4	130
244	Functional Influence of Gene Transfer of Recombinant Nitric Oxide Synthase to Cardiovascular System. , 2000, , 525-545.		3
245	Familial Splenomegaly: Macrophage Hypercatabolism of Lipoproteins Associated with Apolipoprotein E Mutation [Apolipoprotein E (A149 Leu)]. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4354-4358.	1.8	18
246	Improved efficiency of gene transfer to the transplanted lung by retrograde vascular gene delivery. Transplant International, 2000, 13, 241-246.	0.8	1
247	Adventitia-dependent relaxations of canine basilar arteries transduced with recombinant eNOS gene. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1846-H1852.	1.5	18
248	Distribution and function of recombinant endothelial nitric oxide synthase in transplanted hearts. Cardiovascular Research, 1999, 42, 720-727.	1.8	8
249	Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model. Cardiovascular Research, 1999, 43, 798-807.	1.8	44
250	Recombinant Gene Transfer of Endothelial Nitric Oxide Synthase Augments Coronary Artery Relaxations During Hypoxia. Circulation, 1999, 100, II-335-II-339.	1.6	8
251	L-Arginine Availability Is Not Limiting for Nitric Oxide Generation from Recombinant Endothelial Nitric Oxide Synthase. Journal of Vascular Research, 1999, 36, 437-444.	0.6	3
252	Adventitial Expression of Recombinant Endothelial Nitric Oxide Synthase Gene Reverses Vasoconstrictor Effect of Endothelin-1. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 1029-1037.	2.4	12

#	Article	IF	Citations
253	H2O2 is required for UVB-induced EGF receptor and downstream signaling pathway activation. Free Radical Biology and Medicine, 1999, 27, 1197-1202.	1.3	81
254	Absence of toxicity associated with adenoviral-mediated transfer of the Î²-galactosidase reporter gene to neonatal rat islets in vitro. Diabetes Research and Clinical Practice, 1999, 44, 157-163.	1.1	9
255	Endothelial regulation of vascular contraction in radial and internal mammary arteries. Annals of Thoracic Surgery, 1999, 67, 1083-1090.	0.7	40
256	Clomiphene-Induced Severe Hypertriglyceridemia and Pancreatitis. Mayo Clinic Proceedings, 1999, 74, 1125-1128.	1.4	32
257	The Role of Gene Therapy for Intimal Hyperplasia of Bypass Grafts. Circulation, 1999, 100, .	1.6	10
258	Recombinant Gene Transfer of Endothelial Nitric Oxide Synthase Augments Coronary Artery Relaxations During Hypoxia. Circulation, 1999, 100, .	1.6	0
259	Systematic evaluation of distribution of transgene expression after adenovirus-mediated gene transfer to the transplanted heart. Transplant International, 1998, 11, 373-377.	0.8	6
260	Gene Therapy In Lung Transplantation: Effective Gene Transfer Via The Airways. Journal of Thoracic and Cardiovascular Surgery, 1998, 115, 638-643.	0.4	17
261	Transfer and expression of recombinant nitric oxide synthase genes in the cardiovascular system. Trends in Pharmacological Sciences, 1998, 19, 276-286.	4.0	40
262	Transbronchial gene transfer of endothelial nitric oxide synthase to transplanted lungs. Annals of Thoracic Surgery, 1998, 66, 318-323.	0.7	14
263	Hyperlipidemia and Diabetes Mellitus. Mayo Clinic Proceedings, 1998, 73, 969-976.	1.4	131
264	Ex vivo gene transfer of endothelial nitric oxide synthase to atherosclerotic rabbit aortic rings improves relaxations to acetylcholine. Atherosclerosis, 1998, 141, 265-271.	0.4	38
265	Adenovirus-Mediated Gene Transfer of Macrophage Colony Stimulating Factor to the Arterial Wall In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1157-1163.	1.1	22
266	Adventitial Expression of Recombinant eNOS Gene Restores NO Production in Arteries Without Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1231-1241.	1.1	61
267	Influence of temperature on adenovirus-mediated gene transfer. European Journal of Cardio-thoracic Surgery, 1998, 13, 599-603.	0.6	23
268	Expression and Function of Recombinant Endothelial Nitric Oxide Synthase Gene in Canine Basilar Artery After Experimental Subarachnoid Hemorrhage. Stroke, 1998, 29, 1959-1966.	1.0	77
269	Systematic evaluation of distribution of transgene expression after adenovirus-mediated gene transfer to the transplanted heart. Transplant International, 1998, 11, 373-377.	0.8	7
270	Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth.. Journal of Clinical Investigation, 1998, 101, 1557-1564.	3.9	119

#	Article	IF	Citations
271	Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries. Cardiovascular Research, 1997, 35, 553-559.	1.8	36
272	Effects of in vivo adventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12568-12573.	3.3	97
273	Lipids and Lipoproteins in Women. Mayo Clinic Proceedings, 1997, 72, 235-244.	1.4	45
274	Lipoprotein(A) and Diabetes Mellitus. Endocrine Practice, 1997, 3, 324-325.	1.1	0
275	Immunosuppression prolongs adenoviral mediated transgene expression in cardiac allograft transplantation. Cardiovascular Research, 1997, 35, 529-535.	1.8	31
276	Expression and Function of Recombinant Endothelial NO Synthase in Coronary Artery Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2405-2412.	1.1	53
277	The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. Clinical Endocrinology, 1997, 46, 17-20.	1.2	49
278	Adventitial Gene Transfer of Recombinant Endothelial Nitric Oxide Synthase to Rabbit Carotid Arteries Alters Vascular Reactivity. Circulation, 1997, 96, 2254-2261.	1.6	81
279	Enhanced Endothelium-Dependent Relaxations After Gene Transfer of Recombinant Endothelial Nitric Oxide Synthase to Rabbit Carotid Arteries. Hypertension, 1997, 30, 314-320.	1.3	61
280	Expression and Function of Recombinant Endothelial Nitric Oxide Synthase Gene in Canine Basilar Artery. Circulation Research, 1997, 80, 327-335.	2.0	106
281	HDL subparticles and coronary artery disease in NIDDM. Atherosclerosis, 1996, 121, 285-291.	0.4	12
282	Results of Treatment of Pituitary Disease in Multiple Endocrine Neoplasia, Type I. Neurosurgery, 1996, 39, 273-279.	0.6	68
283	Gene Therapy and Inherited Dyslipidemia. Endocrine Practice, 1996, 2, 37-43.	1.1	1
284	The Role of Lipoprotein A-I and Lipoprotein A-I/A-II in Predicting Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 228-231.	1.1	63
285	Multiple endocrine neoplasia type 2B: More than an endocrine disorder. Surgery, 1995, 118, 936-942.	1.0	118
286	Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World Journal of Surgery, 1994, 18, 488-493.	0.8	137
287	Lipids and Lp(a) Lipoprotein Levels and Coronary Artery Disease in Subjects With Non-Insulin-Dependent Diabetes Mellitus. Mayo Clinic Proceedings, 1994, 69, 430-435.	1.4	27
288	Coordinate pulsatile insulin secretion by chronic intraportally transplanted islets in the isolated perfused rat liver.. Journal of Clinical Investigation, 1994, 94, 219-227.	3.9	41

#	Article	IF	Citations
289	Separation of high-density lipoproteins into apolipoprotein E-poor and apolipoprotein E-rich subfractions by fast protein liquid chromatography using a heparin affinity column. Biomedical Applications, 1993, 613, 239-246.	1.7	7
290	Hypertension and Dyslipidemia in Patients With Insulinoma. Mayo Clinic Proceedings, 1993, 68, 141-146.	1.4	41
291	Apolipoprotein A-II Levels and Coronary Artery Disease in Subjects With and Without Diabetes: A Study With Use of a Specific Radioimmunoassay for Apolipoprotein A-II. Mayo Clinic Proceedings, 1993, 68, 556-560.	1.4	7
292	Hyperlipidemia in Patients With Primary and Secondary Hypothyroidism. Mayo Clinic Proceedings, 1993, 68, 860-866.	1.4	157
293	Insulin surrogates in insulinoma. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 448-451.	1.8	32
294	Lipoprotein compositional changes in the fasting and postprandial state on a high-carbohydrate low-fat and a high-fat diet in subjects with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1345-1351.	1.8	6
295	Nicotinic Acid-Induced Toxicity Associated With Cytopenia and Decreased Levels of Thyroxine-Binding Globulin. Mayo Clinic Proceedings, 1992, 67, 465-468.	1.4	27
296	Acute physical exercise alters apolipoprotein E and C-III concentrations of apo E-rich very low density lipoprotein fraction. Atherosclerosis, 1992, 97, 37-51.	0.4	25
297	Serum ferritin in newly diagnosed and poorly controlled diabetes mellitus. Irish Journal of Medical Science, 1992, 161, 636-638.	0.8	19
298	Cushing's syndrome associated with ectopic production of corticotrophinâ€releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma. Clinical Endocrinology, 1992, 37, 460-467.	1.2	95
299	Autonomic Dysfunction and Silent Myocardial Ischaemia on Exercise Testing in Diabetes Mellitus. Diabetic Medicine, 1990, 7, 580-584.	1.2	58
300	Fabryâ€™s disease: A family study. Irish Journal of Medical Science, 1990, 159, 108-109.	0.8	0
301	Usefulness of Biochemical Screening of Diabetic Patients for Hemochromatosis. Diabetes Care, 1990, 13, 532-534.	4.3	47